Medical

Lidocaine Patches Market – Size, Share, Growth and Trends Analysis 2018–2026

Seattle, WA, Aug-12, 2018 — / True Industry News / —

The first FDA approved transdermal lidocaine patch was Lidoderm, in 1999, by Endo Pharmaceuticals Inc. Increasing incidence of back and neck pain is the key factors driving growth of the market.

launched Lidocare, which is first and only patch that is water-free. Lidocare is the new over-the-counter/non-prescription lidocaine pain patch and the technology is under the patenting process. In February 2018, Sorrento Therapeutics, Inc., a subsidiary of Scilex Pharmaceuticals Inc., received U.S. FDA approval for ZTlido 1.8%, with the company’s proprietary adhesion technology. Furthermore, companies are also conducting clinical trials for expanding the application of lidocaine patch for disease and conditions such as Endo Pharmaceuticals, Inc., is conducting clinical trial for the use of lidocaine patch in osteoarthritis, chronic lower back pains, Carpal Tunnel Syndrome etc.

Increasing incidence of the shingles is expected to fuel growth of the lidocaine patches market during the forecast period. Shingles, also known as herpes zoster, leads to the chronic pain known as Post Herpetic Neuralgia (PHN) in which lidocaine patches are used. According to Centers for Disease Control and Prevention (CDC), January 2018, an estimated one third of the total U.S. population develops shingles during their lifetime, which suggests nearly 1 million Americans experiences shingles infection annually. Furthermore, CDC estimated that around 10 to 15% people with shingles infection experience PHN.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1805

launched Lidocare, which is first and only patch that is water-free. Lidocare is the new over-the-counter/non-prescription lidocaine pain patch and the technology is under the patenting process. In February 2018, Sorrento Therapeutics, Inc., a subsidiary of Scilex Pharmaceuticals Inc., received U.S. FDA approval for ZTlido 1.8%, with the company’s proprietary adhesion technology. Furthermore, companies are also conducting clinical trials for expanding the application of lidocaine patch for disease and conditions such as Endo Pharmaceuticals, Inc., is conducting clinical trial for the use of lidocaine patch in osteoarthritis, chronic lower back pains, Carpal Tunnel Syndrome etc.

Lidocaine Patches market report provides key statistics on the market status of the Lidocaine Patches manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Lidocaine Patches industry. The Lidocaine Patches market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.

Key Vendors of Lidocaine Patches Market: This market is highly fragmented, with the presence of Mylan Pharmaceuticals Inc., Endo Pharmaceutical Inc., Teva Pharmaceutical, Inc., Teikoku Pharma USA, Hisamitsu Pharmaceuticals Co. Inc., Galen US Inc., Sorrento Therapeutics, Inc. and Actavis Labs UT Inc. market players.

In the end, the report makes some important proposals for a new project of Lidocaine Patches Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global Lidocaine Patches industry covering all important parameters.

Lidocaine Patches driver

Lidocaine Patches challenge

Lidocaine Patches trend

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1805

Key questions answered in Lidocaine Patches market report:

• What will the market size be in 2020 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1805

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *

Close